More than 900 US medical cannabis dispensaries have become the first operators in the country to hold federal registration, marking the first tangible change for operators since April’s partial rescheduling order.
Tomorrow (July 15, 2026) the landmark administrative hearing on US cannabis rescheduling will come to a close.
This week, what is perhaps the most consequential hearing in the history of the US, and indeed the global cannabis industry, is taking place in Arlington, Virginia.
In the weeks since cannabis under a state medical licence was moved to Schedule III, US multi-state operators (MSOs) have wasted no time in capitalising on the historic reclassification.
Trulieve’s uplisting to the NYSE, the first of its kind in US history, has undoubtedly caught the attention of every large North American cannabis operator.
The US Department of Justice has filed a federal lawsuit seeking $8.3m plus interest from New Jersey-based cannabis multistate operator TerrAscend (TSX: TSND), in what appears to be the first known instance of the government attempting to recover 280E tax refunds made proactively by a cannabis company.
According to recent analysis from the Congressional Research Service, cannabis businesses may not need to wait for rescheduling to challenge the now-notorious 280E tax burden, suggesting that it may be unconstitutional.
As the excitement around President Donald Trump’s executive order to push forward with cannabis rescheduling has faded, the bill is now facing a much harsher reality.
The United States is intensifying its controversial overseas ‘war on drugs’ even as a prolonged government shutdown paralyses domestic policy, a combination that threatens to reshape the outlook for cannabis reform and regulation This morning, news broke that the US military had carried out another series of airstrikes on alleged drug traffickers in the Eastern…
